Showing 501-510 of 3239 results for "".
- FDA OKS Santalis' Phase 2 Study of EISO For ADhttps://practicaldermatology.com/news/fda-oks-santalis-phase-2-study-of-eiso-in-ad/2458385/The U.S. Food and Drug Administration (FDA) has green lighted Santalis Pharmaceuticals Phase 2 clinical study of East Indian Sandalwood Oil (EISO) cream for the treatment of atopic dermatitis (AD). The multi-center, placebo controlled, double blinded, Phase 2 efficacy and tolerability stu
- New Survey: AD Is More Than Skin Deephttps://practicaldermatology.com/news/new-survey-ad-is-more-than-skin-deep/2458417/American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as New York dermatologist Doris Day, MD, who notes that some of the results of the large suvey w
- Launches, Anniversaries and More: Aesthetic News from Around the Webhttps://practicaldermatology.com/news/launches-anniversaries-and-more-aesthetic-news-from-around-the-web/2458425/RealSelf Rolls Out RealSelf Business Pages RealSelf is launching of RealSelf Business Pages so doctors can showcase the full range of providers at a practice as well as the tr
- Venus Concept Unveils Venus Freeze Plus for Non-Invasive Anti-Aging Treatmentshttps://practicaldermatology.com/news/venus-concept-unveils-venus-freeze-plus-for-non-invasive-anti-aging-treatments/2458432/Venus Concept's non-invasive anti-aging device, Venus Freeze Plus, is now available in the US. It is indicated for the treatment of moderate-to-severe facial wrinkles and rhytides, leading to the tightening of the skin, with no pain or downtime. Venus Freeze Plus works by using Venus
- GLOWBIOTICS MD is New Name of mybody Probiotic Skincarehttps://practicaldermatology.com/news/glowbiotics-md-is-new-name-of-mybody-probiotic-skincare/2458440/GLOWBIOTICS MD is the new name of mybody Probiotic Skincare. Currently carried in over 1,000 doctors’ offices across the country and internationally, the five-year-old brand is the first medical-grade
- Topix Pharmaceuticals Introduces All-Trans-Retinol Smoothing Body Lotionhttps://practicaldermatology.com/news/topix-pharmaceuticals-introduces-all-trans-retinol-smoothing-body-lotion/2458439/Topix Pharmaceuticals, Inc. has introduced All-trans-Retinol Smoothing Body Lotion, a retinol body treatment featuring layered ingredient technologies and a powerful delivery system for ultimate penetration. Replenix Smoothing Body Lotion contains the maximum dosage of retinol to be safe
- Kybella for Men May Mean Buh-Bye Beardshttps://practicaldermatology.com/news/kybella-for-men-may-mean-buh-bye-beards/2458456/If Allergan’s double-chin melting injectable Kybella were to really take off among men, we may be seeing a lot fewer beards, jokes bearded Washington DC –based dermatologist Terrence Keaney, MD. Male aesthetics is a growing market,
- It's So Far, So Good for BioPharmX's New Acne Drughttps://practicaldermatology.com/news/its-so-far-so-good-for-biopharmxs-new-acne-drug/2458458/BioPharmX Corporation’s novel topical minocycline, BPX-01, reduced facial P. acnes by more than 90 percent after four weeks, new research shows. In the Phase 2a study, a daily 10 mg dose of topical minocycline offered P. acnes r
- Paratek Initiates Phase 3 Study of Oral Omadacycline for MRSA, Acute Skin Infectionshttps://practicaldermatology.com/news/paratek-initiates-phase-3-study-of-oral-omadacycline-for-mrsa-acute-skin-infections/2458465/The first patient has been dosed in Paratek Pharmaceuticals, Inc.’s second pivotal Phase 3 study of omadacycline for acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a new once-daily oral and IV, well-tolerated
- Alopecia Areata May Protect Against Stroke, Heart Attackhttps://practicaldermatology.com/news/alopecia-areata-may-protect-against-stroke-heart-attack/2458522/Unlike other inflammatory dermatologic conditions, alopecia areata does not appear to increase risk for cardiovascular disease, and it may even protect against stroke, new research suggests. Researchers compared 1,377 alopecia areata patients to 4,131 control subjects. They found th